MRNA Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of -19.69% compared to Moderna, Inc.'s net margin of 31.72%. Moderna, Inc.'s return on equity of -30.18% beat Eli Lilly & Co.'s return on equity of 106.26%.

Moderna, Inc. has a consensus price target of $36.75, signalling upside risk potential of 5.3%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.56%. Given that Moderna, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Moderna, Inc. is more attractive than Eli Lilly & Co..

Moderna, Inc. has a beta of 1.109, which suggesting that the stock is 10.882% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Moderna, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $1B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Moderna, Inc.'s net income of -$200M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 6.06x versus 16.52x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -19.69% compared to Moderna, Inc.'s net margin of 33.68%. Moderna, Inc.'s return on equity of -30.18% beat Merck & Co., Inc.'s return on equity of 39.63%.

Moderna, Inc. has a consensus price target of $36.75, signalling upside risk potential of 5.3%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 5.08%. Given that Moderna, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Moderna, Inc. is more attractive than Merck & Co., Inc..

Moderna, Inc. has a beta of 1.109, which suggesting that the stock is 10.882% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.13% to investors and pays a quarterly dividend of $0.85 per share. Moderna, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $1B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Moderna, Inc.'s net income of -$200M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 6.06x versus 4.13x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of -19.69% compared to Moderna, Inc.'s net margin of -287.29%. Moderna, Inc.'s return on equity of -30.18% beat Novavax, Inc.'s return on equity of --.

Moderna, Inc. has a consensus price target of $36.75, signalling upside risk potential of 5.3%. On the other hand Novavax, Inc. has an analysts' consensus of $12.78 which suggests that it could grow by 85.45%. Given that Novavax, Inc. has higher upside potential than Moderna, Inc., analysts believe Novavax, Inc. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.109, which suggesting that the stock is 10.882% more volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.478%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.

Moderna, Inc. quarterly revenues are $1B, which are larger than Novavax, Inc. quarterly revenues of $70.4M. Moderna, Inc.'s net income of -$200M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Novavax, Inc.'s PE ratio is 3.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 6.06x versus 1.10x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -19.69% compared to Moderna, Inc.'s net margin of 21.32%. Moderna, Inc.'s return on equity of -30.18% beat Pfizer Inc.'s return on equity of 10.84%.

Moderna, Inc. has a consensus price target of $36.75, signalling upside risk potential of 5.3%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 13.54%. Given that Pfizer Inc. has higher upside potential than Moderna, Inc., analysts believe Pfizer Inc. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.109, which suggesting that the stock is 10.882% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.82% to investors and pays a quarterly dividend of $0.43 per share. Moderna, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Moderna, Inc. quarterly revenues are $1B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Moderna, Inc.'s net income of -$200M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 6.06x versus 2.29x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.